These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30539417)

  • 21. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.
    Wang XJ; Saha A; Zhang XH
    Cost Eff Resour Alloc; 2017; 15():17. PubMed ID: 28852326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysis.
    Lai X; Garcia C; Wu D; Knoll MD; Zhang H; Xu T; Jing R; Yin Z; Wahl B; Fang H
    Lancet Reg Health West Pac; 2023 Mar; 32():100666. PubMed ID: 36785861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.
    Pugh S; Wasserman M; Moffatt M; Marques S; Reyes JM; Prieto VA; Reijnders D; Rozenbaum MH; Laine J; Åhman H; Farkouh R
    Infect Dis Ther; 2020 Jun; 9(2):305-324. PubMed ID: 32096144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.
    Wilson M; McDade C; Beby-Heijtel AT; Waterval-Overbeek A; Sundaram V; Perdrizet J
    Infect Dis Ther; 2023 Jul; 12(7):1809-1821. PubMed ID: 37318710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.
    Castañeda-Orjuela C; De la Hoz-Restrepo F
    Vaccine; 2018 Sep; 36(38):5766-5773. PubMed ID: 30087049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
    Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
    Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
    Vaccine; 2024 Oct; 42(23):126043. PubMed ID: 38879409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
    Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
    Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium.
    Wilson MR; McDade CL; Perdrizet JE; Mignon A; Farkouh RA; Wasserman MD
    Infect Dis Ther; 2021 Sep; 10(3):1765-1778. PubMed ID: 34250576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
    Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
    PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data.
    Sings HL; Gessner BD; Wasserman MD; Jodar L
    Infect Dis Ther; 2021 Mar; 10(1):521-539. PubMed ID: 33587245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
    Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
    Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities.
    Li Y; Wang H; Furnback W; Wang BCM; Zhu S; Dong P
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835299
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.
    Hanquet G; Krizova P; Valentiner-Branth P; Ladhani SN; Nuorti JP; Lepoutre A; Mereckiene J; Knol M; Winje BA; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Slotved HC; Fry NK; Rinta-Kokko H; Varon E; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Latasa P; Castilla J; Smith A; Henriques-Normark B; Whittaker R; Pastore Celentano L; Savulescu C;
    Thorax; 2019 May; 74(5):473-482. PubMed ID: 30355641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.